Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Salgotarjan – page 14

270 clinical trials in Salgotarjan, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Salgotarjan at a glance
270
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

270 trials in Salgotarjan

Open in trial search

Study on Benralizumab for Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with Frequent Exacerbations

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Astrazeneca AB

Hypertriglyceridaemia

Not recruiting

Study of ISIS 678354 for Patients with Severe Hypertriglyceridemia

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Atrial fibrillation

Not recruiting

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:HungaryHungary
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of PB016 and Vedolizumab for Patients with Moderately to Severely Active Ulcerative Colitis

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Vedolizumab
  • Sponsor:Polpharma Biologics S.A.

Study of Astegolimab Treatment in Patients with Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Astegolimab
  • Sponsor:F. Hoffmann-La Roche AG

Colitis ulcerative

Not recruiting

Study on Bowel Urgency in Adults with Moderate to Severe Ulcerative Colitis Treated with Mirikizumab

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Mirikizumab
  • Sponsor:Eli Lilly & Co.

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen - Cilag International

Arteriosclerosis

Not recruiting

Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Crohn's disease

Not recruiting

Study on Tulisokibart for Treating Moderate to Severe Crohn's Disease in Adults

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Astrazeneca AB

B-cell lymphoma+1

Not recruiting

Study Comparing Epcoritamab with Chemotherapy for Patients with Relapsed or Refractory B-cell Lymphoma

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Study on OM-85 for Preventing Respiratory Infections in Children with Wheezing Illness (Ages 6 Months to 5 Years)

Registered drug
Countries:HungaryHungary
  • Participants:0–17 years
  • Sponsor:OM Pharma SA

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Salgotarjan

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on hormone receptor-positive and HER2-negative breast cancer treatments, including studies of novel therapeutic combinations and targeted therapies.

  • Advanced metastatic breast cancer treatments
  • Triple-negative breast cancer therapies
  • Hormone therapy resistance studies

Research includes evaluation of new drug combinations and sequential therapy approaches for improved patient outcomes.

02 Lung Cancer Studies

Groundbreaking research on non-small cell lung cancer treatments, particularly focusing on advanced and metastatic cases with specific biomarker profiles.

  • PD-L1 positive NSCLC treatments
  • Combination immunotherapy approaches
  • Stage III unresectable cancer therapies

Studies emphasize personalized treatment approaches based on molecular markers.

03 Head and Neck Cancer

Clinical trials investigating new treatments for head and neck squamous cell carcinoma, including both HPV-negative and recurrent/metastatic cases.

  • Novel combination therapies
  • Immunotherapy applications
  • Treatment for recurrent disease

Research focuses on improving survival rates through innovative therapeutic combinations.

04 Prostate Cancer Innovations

Studies addressing metastatic castration-resistant prostate cancer, evaluating new treatment options and therapeutic combinations.

  • Novel hormonal therapies
  • Treatment-resistant cases
  • Combination therapy approaches

Trials aim to improve outcomes for patients with advanced disease stages.

05 Cardiovascular Research

Studies examining treatments for cardiovascular diseases and related conditions, including stroke prevention and obesity management.

  • Acute ischemic stroke treatments
  • Obesity management in CVD patients
  • Prevention strategies

Research focuses on both therapeutic interventions and preventive approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.